featured
P2Y12 Inhibitor Monotherapy Is Noninferior to Dual Antiplatelet Therapy After PCI
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial
JAMA 2019 Jun 25;321(24)2428-2437, JY Hahn, YB Song, JH Oh, WJ Chun, YH Park, WJ Jang, ES Im, JO Jeong, BR Cho, SK Oh, KH Yun, DK Cho, JY Lee, YY Koh, JW Bae, JW Choi, WS Lee, HJ Yoon, SU Lee, JH Cho, WG Choi, SW Rha, JM Lee, TK Park, JH Yang, JH Choi, SH Choi, SH Lee, HC GwonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.